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Venous Thromboembolism Prophylaxis Compliance Before
and After Electronic Health Record Implementation
Lindsay Saum, PharmD, BCPS, CGP,*,† and David Reeves, PharmD, BCOP*,‡
ABSTRACT
Background: Adherence to American College of Chest Physicians (CHEST) and National Comprehensive Cancer Network (NCCN) guidelines for venous thromboembolism (VTE) prophylaxis helps avoid thromboembolic complications during hospitalization. Electronic health records
(EHR) have the potential to make an impact on guideline adherence, but data are lacking.
Objectives: To determine compliance with VTE prophylaxis guidelines in internal medicine and
oncology populations and to determine whether EHR implementation had any effect on the rate
and appropriateness of prophylaxis practices.
Methods: A retrospective chart review was conducted on medical and oncology patients admitted
to the hospital for a 2-month period pre-EHR and post-EHR implementation. Risk assessment
tools were available pre and post, however they were not mandatory. The rate of VTE prophylaxis
was compared between the 2 time periods, with appropriateness assessed in a subgroup of participants without prophylaxis.
Results: A total of 2,423 patients on the oncology and internal medicine floors were identified
during the pre-EHR (n = 1,171) and post-EHR (n = 1,252) time periods. Patients in the post-EHR
group were less likely to be prescribed prophylaxis as compared to those in the pre-EHR group
(43% vs 50%; P = .001). In the patients audited for proper prophylaxis use (n = 750), significantly
more patients in the post-EHR group had risk factors (84% vs 53%; P < .001) and contraindications (23% vs 8%; P = .001) than in the pre-EHR group. Noncompliance to prophylaxis
in patients who were candidates (positive risk factors without contraindications) occurred more
often in the post-EHR group (51% vs 39%; P < .001).
Conclusion: Implementation of an EHR was associated with an increase in the documentation of
risk factors and contraindications; however, there was a significant decrease in VTE prophylaxis
utilization after EHR implementation.
Key Words—compliance, electronic health record, venous thromboembolism prophylaxis
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V

enous thromboembolism (VTE) is a common occurrence in both internal medicine
and oncology patients, and VTE during
hospitalization accounts for one-fourth of all VTE
events.1 Hospitalization alone is associated with an
8-fold increased risk of VTE, and 50% to 75% of
*

these events occur in patients on the internal medicine floor.1 In a study of 1,180 inpatients, of whom
60.3% were categorized as low risk and 39.7% as
high risk, it was found that VTE occurred in 11%
of high-risk patients who did not receive prophylaxis. Only 0.3% of low-risk patients who did not
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receive prophylaxis experienced a VTE (hazard
ratio [HR], 32.0; 95% CI, 4.1-251.0).2
The American College of Chest Physicians (ACCP)
recommends the Padua Prediction Score to assign risk
stratification for VTE in hospitalized internal medicine
patients to either high or low risk.1 This stratification is
based on factors such as active cancer, previous VTE,
reduced mobility for at least 3 days, known thrombophilic condition, recent trauma, recent surgery, heart
failure, respiratory failure, acute myocardial infarction, acute ischemic stroke, acute infection, obesity,
and ongoing hormonal treatment.2 Because cancer is
a major risk factor, oncology patients are at an even
greater risk of VTE during hospitalization; 3% to 12%
experience VTE in their first hospitalization.3 VTE
increases the likelihood of death by 2- to 6-fold and is
the most common cause of death at 30-day follow-up
in cancer patients undergoing surgery.3 The National
Comprehensive Cancer Network guideline identifies
additional risk factors based on cancer- and treatmentrelated factors. The specific cancers with the highest risk
include pancreatic, brain, stomach, kidney, uterus, lung,
ovary, bladder, and testis tumors. Treatment with certain antineoplastic (diethylstilbestrol, thalidomide, or
lenalidomide) and hormonal compounds is also associated with an increased VTE risk in patients with cancer.
The risk for VTE must outweigh the risk of
a major bleeding event in order for a patient to
receive prophylaxis. For internal medicine patients,
the major risk factors for a major bleeding event are
active gastroduodenal ulcer, bleeding in the 3 months
before admission, and platelet count less than 50 x
109/L.1 Oncology patients are typically at a higher
risk of bleeding than internal medicine patients. In
one study comparing 181 oncology patients and 661
non-oncology patients all receiving VTE prophylaxis,
the 12-month cumulative incidence of major bleeding
was 12.4% and 4.9%, respectively.4
With the implementation of electronic health
records (EHRs) and the ability to create VTE prophylaxis order sets, there is a more uniform and easily
accessible way for physicians to order anticoagulation for their patients. To date, there are no studies
that have examined the impact of EHR implementation on VTE prophylaxis.
The objective of this study was to 
determine
compliance with VTE prophylaxis guideline 

recom
mendations in the internal medicine and 
oncology
populations, and to determine whether the implementation of an EHR has any effect on the rate and
appropriateness of exclusion of VTE prophylaxis use at

St. Vincent Indianapolis Hospital. Our customizable
EHR includes computer physician order entry and
an electronic medication administration record with
barcode verification. During the study period, the
EHR was not used routinely for physician documentation, however it was used for allied health services
documentation.
METHODS
A retrospective, institutional review board–
approved chart review was completed to meet the
study objectives. All medical and oncology patients
admitted to a community teaching hospital in a
2-month period pre-EHR implementation (November 1, 2011 to December 31, 2011) and a 2-month
period post-EHR implementation (November 1, 2012
to December 31, 2012) were evaluated for compliance
with VTE prophylaxis guidelines. The EHR was implemented in February 2012, allowing for a 9-month lead
in period prior to evaluation of the post-EHR period.
Patient treatment was classified as either compliant
or noncompliant based on the CHEST guidelines for
nonsurgical internal medicine patients and the NCCN
guidelines for oncology patients (Table 1).
Compliance rates were compared between the
2 groups to determine whether the implementation of the EHR had any effect on the use of proper
VTE prophylaxis. This compliance rate was calculated based on the entire population (pre-EHR and
post-EHR). If a patient was prescribed VTE prophylaxis, it was assumed to be appropriate. A random
sampling of 750 patients without prophylaxis, split
between the 2 groups, was conducted to further
determine the appropriateness of the lack of pharmacologic prophylaxis. Each patient eligible for
evaluation was assigned a number, and our sample
was determined using a random number generator.
Electronic and paper charts were manually evaluated
for the study endpoints in this sampling of patients.
Patients were labeled as candidates for pharmacologic prophylaxis if they had positive risk factors for
VTE without contraindications to pharmacologic
prophylaxis. Contraindications to pharmacologic
prophylaxis were based on drug, patient, and specific guideline factors (Table 2).
Eligibility Criteria
The study included all patients admitted to the
oncology unit with an oncology diagnosis or seen by
an oncology attending physician or patients admitted to the internal medicine units during the 2-month
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Table 1. Recommended venous thromboembolism prophylactic regimens for hospitalized patients
Internal medicine population
Increased thrombosis risk

Low thrombosis risk

Contraindications to pharmacologic
prophylaxis

Enoxaparin 40 mg SQ daily

None

Graduated compression stockings

Enoxaparin 30 mg SQ q12h

Intermittent pneumatic compression

Enoxaparin 30 mg SQ daily (in renal
impairment)
Fondaparinux 2.5 mg SQ daily
UFH 5000 units q8-12h
Oncology population
Without contraindications to
pharmacologic prophylaxis

With contraindications to pharmacologic prophylaxis

Enoxaparin 40 mg SQ daily

Graduated compression stockings

Enoxaparin 30 mg SQ daily if CrCl <
30 mL/min

Intermittent pneumatic compression

Fondaparinux 2.5 mg SQ daily
UFH 5,000 units SQ q8-12h
Note: CrCl = creatinine clearance; SQ = subcutaneous; q = every; UFH = unfractionated heparin.

Table 2. Oncology and internal medicine patients: Contraindications to prophylaxis
Anticoagulation

Mechanical

• C
 NS bleed, intracranial bleed, or spinal lesion at high
risk for bleeding within 30 days
• Active major bleeding (more than 2 units transfused
in 24 hours)
• Spinal anesthesia/lumbar puncture
• Chronic, clinically significant measurable bleeding > 48
hours
• Platelets < 50,000/mcL
• Severe platelet dysfunction
• Major operation at high risk for bleeding within 24 hours
• Underlying coagulopathy

•
•
•
•
•
•
•

Acute DVT
Large hematoma
Skin ulceration or wounds
Platelets < 20,000/mcL or petechiae
Severe arterial insufficiency (GCS only)
Mild arterial insufficiency (GCS only)
Peripheral neuropathy (GCS only)

Note: CNS = central nervous system; DVT = deep vein thrombosis; GCS = graduated compression stockings.

periods. Patients excluded were those younger than
18 years old, prisoners, and pregnant women.
Data Collection
Data collected included hospital room number,
age, sex, receipt of anticoagulants, and receipt of
mechanical VTE prophylaxis. Patients were evaluated
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to determine whether or not they received pharmacologic VTE prophylaxis. Subsequently, data were collected in a random sampling of patients not receiving
pharmacologic prophylaxis and included demographics (pertinent diagnosis, history of bleeding and/or
clotting disorders, age, sex, height, weight), indications
for VTE prophylaxis, renal function (serum creatinine
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and creatinine clearance as calculated by the Cockcroft-Gault equation), use of mechanical prophylaxis,
risk factors for VTE, and contraindications for pharmacologic VTE prophylaxis. This random sampling
was evaluated to determine whether there was an
appropriate reason for not initiating pharmacologic
prophylaxis per CHEST and NCCN guidelines.
Data Analysis
The primary endpoint of the study was to determine the rates of VTE prophylaxis (pharmacologic
or mechanical) pre- and post-EHR implementation.
Secondary endpoints included the rate of noncompliance with pharmacologic prophylaxis (risk factors
for VTE present, no contraindications present) in a
random sampling of patients not receiving pharmacologic prophylaxis and the rate of risk factor and
contraindication documentation. Subgroup analyses based on service (hematology/oncology, internal
medicine, other) were conducted utilizing the above
outcomes. Patients were placed into 2 groups (preand post-EHR implementation), and data were compared via the chi-square test for nominal data and
Mann-Whitney U test for continuous, nonparametric
data. Data were tested for normality via the ShapiroWilk test. Data were evaluated using IBM SPSS, version 22 (IBM Corp., Armonk, NY).
RESULTS
A total of 2,475 patients on the oncology and
internal medicine floors were identified. Fifty-two
patients were excluded due to incomplete data,
which left an included population of 2,423 during
the pre-EHR (n = 1,171) and post-EHR (n = 1,252)
time periods. Overall, the median age of the population was 63 years, and the majority of the population
was female (57% in the pre- and post-EHR groups).
Prophylaxis (mechanical and pharmacologic) was

utilized in 584 (50%) of the pre-EHR group and 539
(43%) of the post-EHR group (P < .0001) (Table 3).
In the analysis of the random sampling of
patients receiving no pharmacologic prophylaxis
(n = 750), 195 (53%) of the pre-EHR patients and
326 (85%) of the post-EHR patients had risk factors present that made them candidates for VTE prophylaxis (P < .001). Of these patients, 30 (10%) in
the pre-EHR group and 90 (23%) in the post-EHR
group had contraindications to pharmacologic prophylaxis (P < .001). Candidates for pharmacologic
prophylaxis without contraindications who did not
receive prophylaxis included 142 (39%) patients in
the pre-EHR group and 195 (51%) patients in the
post-EHR group (P < .001). Candidates for pharmacologic prophylaxis receiving mechanical prophylaxis were 34 (24%) in the pre-EHR group and 61
(31%) in the post-EHR group (P < .001) (Table 4).
In the internal medicine subgroup of patients not
receiving pharmacologic prophylaxis (n = 431; 185
pre-EHR, 246 post-EHR), risk factors were present
in 75 (41%) and 204 (83%) patients in the pre- and
post-EHR groups, respectively (P < .001) (Table 4).
Statistically significant differences in the contraindications present before and after EHR implementation
were found within the internal medicine subgroup
(6.5% vs 27%; P < .001). Patients who were VTE
candidates based on positive indications for pharmacologic prophylaxis without contraindications were
less prevalent in the pre-EHR group than the postEHR group (24% vs 45%; P < .001).
Likewise, in the hematology/oncology subgroup
of patients not receiving pharmacologic prophylaxis
(n = 186; 97 pre-EHR, 89 post-EHR), 64 (66%)
patients in the pre-EHR group and 84 (94%) patients
in the post-EHR group had risk factors present
(P < .001), while 13 (13%) and 19 (21%) had
contraindications, respectively (P = .151) (Table

Table 3. Demographics of patients identified for study inclusion: Pre- and post-implementation of electronic
health records (EHRs)
Demographics
No. of participants

Pre-EHR

Post-EHR

P value*

1,171

1,252

Received pharmacologic VTE prophylaxis

584 (50%)

539 (43%)

No pharmacologic VTE prophylaxis received

587 (50%)

713 (57%)

63 (29)

63 (29)

.621

505 (43%)

541 (43%)

.97

Age, median years (IQR)
Male

<.001

Note: EHR = electronic health record; IQR = interquartile range; VTE = venous thromboembolism.
*
Level of significance: P < .05, chi-square test.
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Table 4. Sampling of patients not receiving pharmacologic VTE prophylaxis: Pre- vs postimplementation of
electronic health records (EHRs)a

N
Age, median years
(IQR)

All patients

Internal medicine population

Oncology population

Pre-EHR Post-EHR P value*

Pre-EHR Post-EHR P value*

Pre-EHR Post-EHR P value*

366

384

—

185

246

—

97

89

—

64 (28)

63 (28)

.562

69 (33)

66 (31)

.566

64 (28)

63 (28)

.524

Male, n (%)

160 (44)

180 (47)

.385

78 (42)

124 (50)

.090

44 (45)

33 (37)

.252

Receiving
mechanical
prophylaxis (IPC
or GCS), n (%)

107 (29)

134 (35)

.097

77 (42)

124 (50)

.709

18 (19)

23 (26)

.231

At least 1 risk
factor present,
n (%)

195 (53)

326 (84)

<.001

75 (41)

204 (83)

<.001

64 (66)

84 (94)

<.001

Therapeutic
anticoagulation,
n (%)

71 (19)

71 (19)

.751

44 (24)

54 (22)

.653

20 (21)

10 (11)

.082

Contraindications,
n (%)

30 (8)

90 (23)

<.001

12 (6.5)

66 (27)

<.001

13 (13)

19 (21)

.151

Candidates for
142 (39)
pharmacologic
prophylaxis, n (%)

195 (51)

<.001

45 (24)

110 (45)

<.001

47 (48)

57 (64)

.032

Candidates for
pharmacologic
prophylaxis
receiving
mechanical
prophylaxis, n (%)

61 (16)

<.001

19 (10)

38 (15)

.012

9 (9)

16 (18)

.063

34 (9)

Note: EHR = electronic health record; GCS = graduated compression stockings; IPC = intermittent pneumatic compression; IQR = interquartile range;
VTE = venous thromboembolism
a
Patients included in this analysis are from a random sampling of patients included in the study and not receiving pharmacologic VTE prophylaxis.
*
Level of significance: P < .05, chi-square test.

4). 
Candidates for pharmacologic prophylaxis
without contraindications who did not receive
prophylaxis included 47 (48%) patients and 57
(64%) patients in the pre- and post-EHR groups,
respectively (P = .032).
DISCUSSION
The results of this study indicate that the implementation of an EHR at a community teaching
hospital was associated with a decrease in the use
of VTE prophylaxis. Before this study, no studies
evaluated the compliance rates of VTE prophylaxis
before and after EHR implementation. There are
data supporting the utilization of clinical decision
support tools (CDST) within the EHR and their
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impact on VTE prophylaxis compliance.5-7 Haut
and colleagues conducted a study to examine documentation and compliance to guidelines in a trauma
population before and after a mandatory risk factor
stratification tool and orderset.6 They found that
both documentation and compliance increased following implementation (3% vs 97.8% and 66.2%
vs 84.4%, respectively; P < .001). Novis and colleagues found a significant increase in compliance
in a surgical population, however not to the same
extent as the study by Haut and colleagues (14%
vs 36%; P < .001).4 Compared to the previous
2 studies, MaCauley and associates evaluated VTE
prophylaxis compliance rates in a broader patient
population that included medicine patients.7 They

VTE Prophylaxis Compliance and EMR Implementation

assessed VTE prophylaxis compliance rates in
patients categorized as low risk from their clinical decision support tool. Similar to surgical and
trauma patient populations, there was a significant
increase in the compliance rates after implementation (27% vs 34%; P < .0001). There is currently no
published literature to support the use of CDST in
the hematology and oncology population.
The VTE risk assessment tool and order set inclu
ded in our EHR were not mandatory upon the implementation of the EHR, and this may explain the differences in compliance rates between our study and
published literature. This same assessment tool was
available to be used both pre- and post-EHR implementation on either paper or in the EHR, respectively. The assessment tool included a list of common
risk factors for VTE and placed the patients into a
low-, moderate-, or high-risk category. There was
space available for documentation of contraindications to pharmacologic VTE prophylaxis on both
versions. Upon further investigation, we discovered
that the VTE risk assessment tool in the EHR was
not provider-friendly during the study period. This
may have led to decreased pharmacologic prophylaxis orders in our post-EHR time period. We tried
to eliminate any initial EHR difficulties and growing
pains by starting our post-EHR time period 8 months
after the system was adopted.
This was a single-center study with two,
2-month time frames. Because the data were collected over a short time frame, it is possible that
many of the same physicians were working during
both periods; the study may have missed the practice habits of physicians not on either service during the 2-month period. This could have introduced
bias into the results, because some physicians may
be more likely than others to prescribe VTE prophylaxis to their patients; however, it is unlikely
that varying practice patterns would have resulted
in a significant increase in the use of VTE prophylaxis. In future studies, it is recommended that data
be collected over a longer period of time or that a
random sampling of patients who were treated by
different physicians be taken.
The percentage of patients who received
mechanical prophylaxis may be falsely high. Often
times when mechanical prophylaxis is ordered, the
patients refuse to wear them. That being said, that
percentage of patients who did not receive any prophylaxis, including mechanical, may be falsely low
due to the possible lack to documentation of non-

compliance. Unless it was documented in a clinical
note that a patient was not using mechanical prophylaxis, we made the assumption that the patient
was compliant.
Although rates of VTE prophylaxis decreased,
after implementation of the EHR there was a statistically significant increase in the identification of
contraindications to VTE prophylaxis and risk factors for development of VTE. We expected to see
this increase but cannot conclude that the EHR
makes it easier to identify risk factors and contraindications. Without further data collection on the
entire population, we cannot determine whether the
patient populations had similar baseline risk factors
and contraindications or if the postimplementation
group had a statistically significant difference in
risk factors. Despite the increase in documented risk
factors post-EHR implementation, the rate of prophylaxis decreased. We were also unable to determine whether or not the physicians viewed the risk
factors and contraindications or whether they were
aware of all the risk factors and contraindications
to prophylaxis.
CONCLUSION
Implementation of the EHR at a community
teaching hospital was associated with a decreased
overall rate and appropriateness of VTE prophylaxis
practices and an increase in risk factor and contraindication documentation. The implementation of
an EHR with computerized physician order entry
in itself will not ensure an increase in VTE prophylaxis rates. The passive availability of an order set
without a mandatory risk assessment followed by
CDSTs allowed practice to continue unchanged with
a decline in prophylaxis rates. To increase the likelihood of success, CDSTs and mandatory assessment
should be implemented within the EHR.
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